<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01951599</url>
  </required_header>
  <id_info>
    <org_study_id>D5160C00005</org_study_id>
    <nct_id>NCT01951599</nct_id>
  </id_info>
  <brief_title>To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.</brief_title>
  <official_title>A Phase I, Open-label, Single-center, Sequential Design Study in Healthy Volunteers to Determine the Relative Bioavailability of Different Oral Formulations of AZD9291 and the Effect of Food</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the relative bioavailability of different oral formulations of AZD9291 and the
      effect of food in healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open-label, Single-center, Sequential Design Study in Healthy Volunteers to
      Determine the Relative Bioavailability of Different Oral Formulations of AZD9291 and the
      Effect of Food
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2013</start_date>
  <completion_date type="Actual">June 4, 2014</completion_date>
  <primary_completion_date type="Actual">June 4, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of maximum plasma concentration (Cmax)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites by assessment of the area under the plasma concentration-time curve from zero to infinity (AUC)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of time to Cmax (tmax)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of Terminal rate constant (λz)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of Terminal half life (t1/2,λz)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of lag time before observation of quantifiable analyte concentrations in plasma (tlag)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of area under the plasma concentration-time curve from zero to time of last measurable concentration [AUC(0-t)]</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 and its metabolites, by assessment of area under the plasma concentration-time curve from zero to 72 hours [AUC(0-72)]</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 only, by assessment of apparent plasma clearance (CL/F).</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 only, apparent volume of distribution (Vz/F)</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of AZD9291 parent to metabolite ratio (calculated for both Cmax and AUC).</measure>
    <time_frame>Blood samples are collected pre dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 216, 336, 504 hours post dose</time_frame>
    <description>Curve taken during each of the 5 treatments</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety variables (adverse events, physical exam, vital signs, ECG's, clinical laboratory safety tests, opthalmological examination)</measure>
    <time_frame>Baseline (Day-1) to Day 28</time_frame>
    <description>Assessments performed during each of the 5 treatments.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AZD9291 20mg (oral capsule fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive AZD9291 20mg administered by mouth, as a capsule, in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9291 20mg (oral solution fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive AZD9291 20mg administered by mouth, as a solution, in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9291 20mg (oral tablet fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive AZD9291 20mg administered by mouth, as a tablet, in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9291 20mg (oral fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD9291 20mg (oral fed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Volunteers will receive AZD9291 20mg administered by mouth, as a capsule or tablet in the fed state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291</intervention_name>
    <description>Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).</description>
    <arm_group_label>AZD9291 20mg (oral capsule fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291</intervention_name>
    <description>Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).</description>
    <arm_group_label>AZD9291 20mg (oral solution fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291</intervention_name>
    <description>Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).</description>
    <arm_group_label>AZD9291 20mg (oral tablet fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291</intervention_name>
    <description>Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.</description>
    <arm_group_label>AZD9291 20mg (oral fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9291</intervention_name>
    <description>Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.</description>
    <arm_group_label>AZD9291 20mg (oral fed)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1, Body mass index between 19 and 30 kg/m2 and weight at least 50 kg and no more than 100
        kg. 2, Volunteers must be willing to use a condom, unless their partners are
        postmenopausal, surgically sterile, or using an effective hormonal method of contraception
        or intrauterine coil. 3. In addition, volunteers must agree to continue to take similar
        contraceptive precautions until 4 months after the last dose of AZD9291.

        Exclusion Criteria:

          1. Any clinically relevant abnormalities in physical examination, vital signs,
             hematology, clinical chemistry, urinalysis or ECG at baseline in the opinion of the
             Investigator.

          2. Volunteers who have received live or live-attenuated vaccine in the 2 weeks prior to
             dosing.

          3. History of severe allergy/hypersensitivity or or ongoing allergy/hypersensitivity, as
             judged by the Investigator, or history of hypersensitivity to AZD9291, its excipients,
             or drugs with a similar chemical structure or class.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Leese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles 6700 W 115th Street, Kansas, US</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1901&amp;filename=D5160C00005revised_csp_2_signed_31March%2016_REDACTED.PDF</url>
    <description>D5160C00005revised_csp_2_signed_31March 16_REDACTED</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1901&amp;filename=D5160C00005_CSR_Synopsis_pdf..pdf</url>
    <description>D5160C00005_CSR_Synopsis</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2013</study_first_submitted>
  <study_first_submitted_qc>September 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2013</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I, healthy, bioavailability, pharmacokinetics, safety, tolerability.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

